Innoviva, Inc.
- Jurisdiction
United States - LEI
549300ACOX4QTBES6535 - ISIN
US45781M1018 (INVA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€37.14 147.6% undervalued - Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€315.79M - Gross margin
88.3% - EBIT
€2.31M - EBIT margin
0.7% - Net income
€32.97M - Net margin
10.4%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
- Last dividend amount
-
$0.25 - Ex date
-
- Payment date
-
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| George Whitesides | April 23, 2025 | $300.00K–$600.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: February 8, 2018 (Q4 2017)